Adalimumab Injection

Effects and efficacy:
Adalimumab injection can be used to treat rheumatoid arthritis and ankylosing spondylitis, and can improve symptoms such as joint stiffness, pain, redness, swelling and deformation. This product is used in combination with methotrexate to treat moderate to severe active rheumatoid arthritis that is ineffective with disease-modifying antirheumatic drugs (including methotrexate). It is used for adult patients with severe active ankylosing spondylitis who are ineffective with conventional treatment.
Usage and dosage:
For adult patients with rheumatoid arthritis, the recommended dosage is 40 mg once, subcutaneously once every two weeks. Methotrexate should be continued during medication. If the effect of monotherapy decreases, the dosage can be increased to once a week under the guidance of a doctor. During the treatment with this product, glucocorticoids, salicylic acid drugs, non-steroidal anti-inflammatory drugs or analgesics can continue to be used. For adult patients with ankylosing spondylitis, the recommended dosage is 40 mg once, subcutaneously injected once every two weeks. For all the above indications, clinical response can usually be obtained within 12 weeks of treatment. If the patient does not show clinical response during the treatment period, the doctor should be consulted in time to evaluate whether to continue the treatment with this product. Existing data show that the use of adalimumab injection again after an interval of 70 days or more will achieve the same degree of clinical response and safety as before the interruption of administration.
Adverse reactions:
The most serious adverse reactions of this product are severe infection, neurological function effects, and certain malignant tumors of the lymphatic system. The most common adverse reactions are infection (such as nasopharyngitis, upper respiratory tract infection and sinusitis), injection site reaction (erythema, itching, bleeding, pain or swelling), headache and skeletal muscle pain. Most injection site reactions are mild and do not require discontinuation of the drug.
Drug contraindications:
Allergic to this product is contraindicated during pregnancy and lactation. Use with caution in patients with hepatic and renal insufficiency.